2019 Biosimilars Insurance Coverage and Processing 
Pharmacy Times
JULY 1, 2025
SHOW MORE Pharmacists can help oversee the treatment process to ensure patients with transthyretin amyloid cardiomyopathy (ATTR-CM) are adhering to tafamidis. Ongoing research explores tafamidis' long-term efficacy, potential in other heart failure forms, and combination therapies for enhanced outcomes.
pharmaphorum
JULY 7, 2025
Skip to main content Monday 7 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
AUGUST 7, 2025
According to a report from GlobalData , parent company of Pharmaceutical Technology , the value of mRNA licensing deals held 800% more value in 2024 than in 2019. mRNA vaccine coverage on Pharmaceutical Technology (or Clinical Trials Arena) is supported by Trilink. Give your business an edge with our leading industry insights.
PharmaShots
JUNE 28, 2023
The increase in ENBREL sales for 2019 vs 2018 was primarily driven by favorable changes to estimated sales deductions and an increase in net selling price, partially offset by lower unit demand. Some of its approved biosimilars are mentioned below along with the regulatory bodies they are approved by*. Enbrel Prescribing Information 3.
Pharmaceutical Commerce
JUNE 13, 2025
The research firm 46brooklyn did a nice summary of the average price increases from 2012 to 2024 (see chart below), and you can clearly see the shift in behavior from the height of the bubble growth in 2019. The loophole I just described was what he used to process that increase. to $750 per pill.
FDA Law Blog: Biosimilars
OCTOBER 29, 2023
Since that blog post, an important step forward was the decoupling of the coverage requirement from the FDA Birth Control Guide in the guidance provided by the Department to plans and issuers.
Expert insights. Personalized for you.
Let's personalize your content